Medicare Enrolled
Dr. Daniel Greenwald, M.D.
Medical Oncology · Santa Barbara, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Greenwald from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Greenwald?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Greenwald
Dr. Daniel Greenwald is a medical oncology specialist in Santa Barbara, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Greenwald performed 115,008 Medicare services across 2,444 unique beneficiaries.
Between the years covered by Open Payments, Dr. Greenwald received a total of $173,659 from 48 pharmaceutical and/or device companies across 235 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Greenwald is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in CA
$173,659 industry payments
Medicare Practice Summary
Medicare Utilization ↗115,008
Medicare services
Top 4% in CA for medical oncology
2,444
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,053 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 36,800 | $43 | $213 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
32,220 | $38 | $203 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
18,700 | $2 | $20 |
| Denosumab injection (Prolia/Xgeva) | 10,380 | $19 | $96 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,150 | $0 | $10 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,430 | $1 | $95 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,426 | $102 | $858 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,376 | $0 | $5 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
791 | $8 | $58 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
677 | $1 | $10 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
633 | $8 | $25 |
| Anti-nausea injection (ondansetron/Zofran) | 592 | $0 | $11 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
546 | $14 | $245 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
520 | $148 | $960 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
481 | $120 | $1,064 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
278 | $12 | $122 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
277 | $67 | $451 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
218 | $2 | $271 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
212 | $100 | $680 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
142 | $67 | $508 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
112 | $27 | $475 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 105 | $129 | $4,038 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
103 | $25 | $550 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
101 | $58 | $388 |
| New patient office visit, complex (60-74 min) | 100 | $180 | $1,360 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
92 | $59 | $620 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
87 | $30 | $282 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
74 | $2 | $25 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
73 | $1 | $10 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
67 | $65 | $470 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
52 | $19 | $150 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
47 | $1 | $15 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
39 | $12 | $225 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
34 | $30 | $309 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
28 | $34 | $397 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
18 | $35 | $187 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
16 | $129 | $1,085 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
11 | $146 | $1,320 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.5% high complexity
95.0% medium
3.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$173,659
Total received (2018-2024)
Avg $24,808/year across 7 years
Top 11% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
48
Companies
235
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$112,170 (64.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$57,587 (33.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,902 (2.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$19,199
2023
$32,110
2022
$32,175
2021
$28,357
2020
$27,661
2019
$19,040
2018
$15,117
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$8,483
Lilly USA, LLC
$6,892
BeiGene USA, Inc.
$1,950
ADC Therapeutics America, Inc.
$1,550
ABBVIE INC.
$153
Sumitomo Pharma America, Inc.
$106
PFIZER INC.
$27
Tempus AI, Inc
$20
Agios Pharmaceuticals, Inc.
$19
Top 3 companies account for 90.2% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$69,059
ADC Therapeutics America, Inc.
$46,039
Lilly USA, LLC
$11,995
Jazz Pharmaceuticals Inc.
$7,943
E.R. Squibb & Sons, L.L.C.
$7,129
Genentech, Inc.
$5,929
BeiGene USA, Inc.
$5,358
MorphoSys, US Inc.
$4,345
AstraZeneca Pharmaceuticals LP
$4,048
Exelixis Inc.
$3,431
JAZZ PHARMACEUTICALS INC.
$2,637
Karyopharm Therapeutics Inc.
$2,272
Athenex Pharmaceutical Division, LLC
$350
Pharmacyclics LLC, An AbbVie Company
$317
AbbVie, Inc.
$222
ABBVIE INC.
$217
Incyte Corporation
$215
Takeda Pharmaceuticals U.S.A., Inc.
$191
TESARO, Inc.
$180
Janssen Scientific Affairs, LLC
$138
Clovis Oncology, Inc.
$123
Eisai Inc.
$117
Blueprint Medicines Corporation
$116
Spectrum Pharmaceuticals Inc.
$109
Gilead Sciences, Inc.
$106
Sumitomo Pharma America, Inc.
$106
GENZYME CORPORATION
$102
Celgene Corporation
$102
ImmunoGen, Inc.
$101
Merck Sharp & Dohme Corporation
$100
PFIZER INC.
$75
Progenics Pharmaceuticals, Inc.
$70
Seattle Genetics, Inc.
$54
Seagen Inc.
$49
Myriad Genetic Laboratories, Inc.
$33
PORTOLA PHARMACEUTICALS, INC.
$32
EMD Serono, Inc.
$29
Rigel Pharmaceuticals, Inc.
$25
Array BioPharma Inc.
$24
EUSA Pharma (US) LLC
$24
Amgen Inc.
$21
Tempus AI, Inc
$20
Novartis Pharmaceuticals Corporation
$20
Agios Pharmaceuticals, Inc.
$19
Flowonix Medical Incorporated
$19
Puma Biotechnology, Inc.
$18
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
Janssen Biotech, Inc.
$15
Top 3 companies account for 73.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ANDEXXA · AYVAKIT · Abraxane · BAVENCIO · BRUKINSA · Braftovi · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · ELREXFIO · EPKINLY · Elahere · FASLODEX · Folotyn · GAZYVA · GILOTRIF · IMBRUVICA · INLYTA · Imbruvica · JAKAFI · JAYPIRCA · JEVTANA · KEYTRUDA · KISQALI · LORBRENA · LYNPARZA · Lenvima · Lunsumio · Lupron · MONJUVI · MYRISK · NINLARO · Nerlynx · Neulasta · Non-Covered Product · OPDIVO · ORGOVYX · POLIVY · PYLARIFY · PYRUKYND · Polivy · Pomalyst · Prometra II · REBLOZYL · Rubraca · SARCLISA · Sylvant · TEPMETKO · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · VYXEOS · Venclexta · XALKORI · XPOVIO · XT CDX · ZEJULA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (65%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Medical oncologists within 10 mi
2
Per 100K population
0.5
County median income
$95,977
Nearest hospital
SANTA BARBARA COTTAGE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Greenwald is a mixed practice specialist, with above-average Medicare volume (top 4% in CA), with speaking/promotional industry engagement in the top 11% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Greenwald experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Greenwald performed 36,800 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Greenwald receive payments from pharmaceutical companies?
Yes. Dr. Greenwald received a total of $173,659 from 48 companies across 235 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Greenwald's costs compare to other medical oncologists in Santa Barbara?
Dr. Greenwald's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Greenwald) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Santa Barbara
Browse medical oncologists in Santa Barbara ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
ADC Therapeutics America, Inc. Payments to Doctors
See all physicians who received payments from ADC Therapeutics America, Inc.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology